CoVaRR-Net Funded Research Results

CoVaRR-Net Funded Research Results2022-08-09T12:55:08-04:00

Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics

January 9, 2023|Funded Research Results, Pillar 10|

An international team of researchers led by CoVaRR-Net Pillar 10 Lead Dr. François Jean (Professor of Virology, Department of Microbiology and Immunology, University of British Columbia) investigated a catalogue of more than 350 compounds derived from natural sources including plants, fungi, and marine sponges in a bid to identify new antiviral drugs to treat COVID-19 variants such as omicron.

Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants

November 7, 2022|Funded Research Results, Pillar 3|

Mutations to the spike protein of the Omicron variant of SARS-CoV-2 have evolved to an extent not observed in previous variants of concern (VOCs). This raises concerns regarding its potential for increased antibody evasion, with the subsequent ability to cause infections and disease in people presumed to have adequate immunity.

Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine but strong initial responses to a third dose

November 2, 2022|Funded Research Results, Pillar 1|

Booster doses of COVID-19 mRNA vaccine are widely recommended to maintain immunity against SARS-CoV-2, but longer-term studies of vaccine-induced responses remain limited, particularly among older adults and individuals who have experienced an Omicron breakthrough infection following vaccination.

Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after three doses of COVID-19 mRNA vaccine

November 2, 2022|Funded Research Results, Pillar 1|

Booster doses of COVID-19 mRNA vaccine are widely recommended to maintain immunity against SARS-CoV-2, but longer-term studies of vaccine-induced responses remain limited, particularly among older adults and individuals who have experienced an Omicron breakthrough infection following vaccination.

Identifying markers of emerging SARS-CoV-2 variants in patients with secondary immunodeficiency

November 2, 2022|Funded Research Results, Pillar 3|

Serial sequencing of the SARS-CoV-2 genome in immunosuppressed patients receiving antiviral treatments and/or antibodies suggests that high viral load in these hosts allows for a rapid emergence of new treatment-resistant variants. For instance, all available data suggests that the Omicron variant developed in an immunocompromised patient.

A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS -CoV-2 infection

September 30, 2022|Funded Research Results, Pillar 3|

The presentation of a vaccine antigen to the immune cells is critical to obtain an efficient immune response. It is known that nanostructures that are made of protein subunits assembled into a highly repetitive and crystalline arrangement are excellent inducers of the antibody response.

Go to Top